[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,236,800
  • Shares Outstanding, K 87,861
  • Annual Sales, $ 218,710 K
  • Annual Income, $ -113,700 K
  • EBIT $ -217 M
  • EBITDA $ -222 M
  • 60-Month Beta -0.10
  • Price/Sales 14.76
  • Price/Cash Flow N/A
  • Price/Book 2.69

Options Overview Details

View History
  • Implied Volatility 59.02% (+1.70%)
  • Historical Volatility 39.11%
  • IV Percentile 8%
  • IV Rank 8.96%
  • IV High 198.61% on 03/19/26
  • IV Low 45.28% on 07/22/26
  • Expected Move (DTE 9) 0.85 (2.30%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 7
  • Volume Avg (30-Day) 67
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 2,270
  • Open Int (30-Day) 3,626
  • Expected Range 36.11 to 37.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.08
  • Number of Estimates 3
  • High Estimate $-0.72
  • Low Estimate $-1.30
  • Prior Year $1.33
  • Growth Rate Est. (year over year) -181.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.01 +8.67%
on 07/23/26
37.90 -2.48%
on 07/24/26
-0.03 (-0.08%)
since 07/10/26
3-Month
26.81 +37.86%
on 06/10/26
40.58 -8.92%
on 07/07/26
+8.84 (+31.44%)
since 05/12/26
52-Week
23.23 +59.10%
on 09/08/25
40.58 -8.92%
on 07/07/26
+13.37 (+56.68%)
since 08/12/25

Most Recent Stories

More News
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Aug. 4, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

SOUTH SAN FRANCISCO, Calif. , July 27, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that initiation of Part 2 monotherapy...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

SOUTH SAN FRANCISCO, Calif. , July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted...

IDYA : 36.96 (+0.33%)
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

SOUTH SAN FRANCISCO, Calif. , June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has...

IDYA : 36.96 (+0.33%)
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif. , June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common...

IDYA : 36.96 (+0.33%)
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.

IDYA : 36.96 (+0.33%)
JNJ : 260.86 (+0.41%)
INCY : 120.77 (-0.25%)
TNGX : 25.58 (-2.89%)
RHHBY : 56.5100 (-0.19%)
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif. , June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants....

IDYA : 36.96 (+0.33%)
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif. , June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock...

IDYA : 36.96 (+0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 38.03
2nd Resistance Point 37.61
1st Resistance Point 37.29
Last Price 36.96
1st Support Level 36.55
2nd Support Level 36.13
3rd Support Level 35.81

See More

52-Week High 40.58
Last Price 36.96
Fibonacci 61.8% 33.95
Fibonacci 50% 31.91
Fibonacci 38.2% 29.86
52-Week Low 23.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.